The long-held expectation that the global market for anti-obesity drugs will reach $150 billion in the next decade appears less certain. The FDA has approved Novo Nordisk's first diet pill with the active ingredient semaglutide (GLP-1), which is identical to Wegovy but given orally instead of by injection. The starting dose costs $149 a month and the drug will hit the market in early 2026. In clinical trials, patients lost an average of more than 16 percent of their body weight. The market for these drugs could be worth up to $100 billion. Shares in Novo Nordisk jumped about 10 percent after the approval was announced.[1]